30 results
Page 2 of 2
S-4
EX-10.37
5zo7anjcuucim2
23 Jun 20
Registration of securities issued in business combination transactions
12:28pm
8-K
EX-99.1
67hry4kt5yuxnfu6s
7 May 20
Results of Operations and Financial Condition
7:46am
8-K
EX-99.1
m1hsxu54f3a 0r1
12 Mar 20
Results of Operations and Financial Condition
8:00am
8-K
EX-99.1
gand589w
5 Nov 19
Top-line data from PROTECTOR 1 study expected by early first quarter of 2020
8:00am
8-K
EX-99.1
2397f5
14 Aug 19
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
hlptlr1qrgmlq
15 May 19
Results of Operations and Financial Condition
9:00am
8-K
EX-99.1
hlfb7i5 722hntzmqsh
18 Mar 19
Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19
4:02pm
8-K
EX-99.1
puto7yq gysm5ax6
13 Nov 18
Initiation of pivotal Phase 3 program of RTB101 in RTIs expected in 1H19
8:10am
8-K
EX-99.1
f3s o8u3699
9 Aug 18
Results of Operations and Financial Condition
8:15am
8-K
EX-99.1
qo54l9q 8um21
10 May 18
Last patient dosed in Phase 2b trial; topline data now expected in third quarter of 2018
12:00am